The Top Companies Poised to Win from Cannabis 2.0 in Canada

September 30, 2019 -

Over the next three weeks, Canada’s Cannabis 2.0 is expected to create even more opportunity for CBD companies. In fact, on October 17, 2019, the country will legalize edibles, beverages, and topicals just a year after approving dried cannabis flower, oils, and sprays. Analysts at Deloitte already believe Cannabis 2.0 could create a C$2.7 billion opportunity. It’s already expected to benefit includes Aurora Cannabis (NYSE:ACB)(TO:ACB), which recently announced its expansion into edibles, vapes, and concentrates. Canopy Growth just announced at the Barclays 2019 Global Consumer Staples Conference that Cannabis 2.0 would be a major catalyst for the company over the next 12 to 18 months. Other top beneficiaries include The Yield Growth Corp. (CSE:BOSS)(OTC:BOSQF),  Charlotte’s Web Holdings Inc. (CN:CWEB)(OTC:CWBHF), Aphria Inc. (NYSE:APHA)(TO:APHA), GW Pharmaceuticals (NASDAQ:GWPH), and OrganiGram Holdings Inc. (TSX:OGI)(NASDAQ:OGI).

The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS: The Yield Growth Corp. just announced that five more Urban Juve products have each received a Compliance Certificate completing registration of the products in the European Union, bringing the total number of European registered products to eight. The newly approved products include Terpene-Rich Face Moisturizer with Hemp Oil & Pomegranate Oil for Dry Skin, Terpene-Rich Face Moisturizer with Hemp Oil & Helichrysum Flower Water for Oily Skin, Hydrating Body Oil, Nurturing Body Oil and Energizing Body Oil.

Urban Juve is expecting European approval within the month for three additional products currently for sale in North America, and it has begun the registration process for 4 more products - an all-natural deodorant and Tinted Hemp Oil Lip Therapy in 3 colors. Urban Juve is a hemp-powered skin care line the brings together Ayurvedic teachings and modern science. It is focused on delivering true rejuvenation from the inside out. Its natural, effective products are infused with high quality botanicals, including hemp root oil which is crafted through its proprietary extraction process. Urban Juve products are targeted to the wellness-conscious consumer, with a primary target market of Millennials (ages 22 - 37) and a strong secondary market of Gen X (ages 38 - 53).

Urban Juve products will be featured in the Vogue Beauty Highlight sections of this year’s September, October and November issues of UK Vogue, each with an expected audience of 4.1 million readers. Also, Urban Juve will be featured in UK Vanity Fair’s first ever beauty showcase in the November 2019 issue. With increasing brand exposure in the UK, Urban Juve is now looking to secure a distribution alliance in the United Kingdom. Urban Juve is building a robust international distribution platform with distribution partners who have access to 44,000 retail points of sale. Recently, Urban Juve announced distribution deals in Canada, Columbia, Brazil, Greece and Cyprus. As proposed legislation across the European Union continues to bring cannabis closer to the mainstream, high-end cannabis products are gaining popularity. With a total population over 508 million, the EU represents massive market potential for Urban Juve products.

Other related cannabis industry developments include:

Charlotte’s Web Holdings Inc. (CN:CWEB)(OTC:CWBHF) announced that The Vitamin Shoppe, an omni-channel, specialty retailer of nutritional products, has commenced selling the new line of Charlotte's Web CBD hemp extract-infused CBD gummies in 738 stores across 45 U.S. states. This expands Charlotte's Web product offerings carried by The Vitamin Shoppe to include CBD hemp extract oil tinctures, liquid capsules, and now gummies. Charlotte's Web gummies are a popular edible format providing measurable consumption of convenient bite-sized full-spectrum CBD hemp extract. Charlotte's Web gummies, launched in June of this year, are made with whole-plant extract from its prized hemp genetics featuring synergistic functional ingredients to support specific health related functions including everyday stress, sleep, and recovery from exercise or active lifestyles. "This nationwide pickup of our popular new gummy line by The Vitamin Shoppe is very exciting to report," said Charlotte's Web CEO Deanie Elsner. "Working with a trusted retail partner that is dedicated to helping its customers become their best self, allows us to effectively expand our national footprint giving more Americans retail access to our leading CBD hemp extract wellness products. We are thrilled about The Vitamin Shoppe's decision to expand their offering with our new chewable gummies."

Aphria Inc. (NYSE:APHA)(TO:APHA) just announced the launch of its cannabis education program ‘Aphria Educates’. This program is mandated to educate Canadian adults on responsible and safe use of all cannabis products legally available now and in the future. The first Aphria Educates event will be a two-city educational panel in conjunction with Drugs Free Kids Canada (DFK), a Canadian non-profit organization providing parents with evidence-informed information about youth and substance use while promoting frequent, balanced parent-youth discussions about drugs. Entitled Aphria Educates with Drug Free Kids Canada, the panels will focus on furthering awareness around the potential harms of cannabis for youth and help parents navigate the ever-evolving Canadian cannabis landscape. The Aphria Educates with Drugs Free Kids Canada initiative follows the 2018 Charter Agreement entered into by Aphria and DFK solidifying their commitment to ongoing cannabis education. “Cannabis education is a cornerstone of our Corporate Social Responsibility platform and is paramount in everything we do at Aphria Inc. We are proud to launch Aphria Educates, an engaging program that is designed to educate on the safe and responsible use of legal cannabis,” said Irwin D. Simon. “There is no better partner than Drug Free Kids Canada to help kick off this first initiative of Aphria Educates, which we believe will deliver important information and will encourage necessary dialogue among Canadian parents and their children.”

GW Pharmaceuticals PLC (NASDAQ:GWPH) just announced that the European Commission (EC) has approved the marketing authorization for EPIDYOLEX for use as adjunctive therapy of seizures associated with Lennox‑Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older. The approval paves the way for the launch of the medicine across Europe. “The approval of EPIDYOLEX marks a significant milestone, offering patients and their families the first in a new class of epilepsy medicines and the first and only EMA-approved CBD medicine to treat two severe and life-threatening forms of childhood-onset epilepsy,” said Justin Gover, GW’s CEO. “This approval is the culmination of many years of dedication and collaboration between GW, physicians and the epilepsy community. We believe patients and physicians deserve access to rigorously tested and evaluated cannabis-based medicines, manufactured to the highest standards and approved by medicines regulators, and we are delighted to be the first to offer this solution to the epilepsy community.”

OrganiGram Holdings Inc. (TSX:OGI)(NASDAQ:OGI) just announced that effective September 6, 2019 it has received Health Canada’s approval for the licensing of 17 additional cultivation rooms under the Cannabis Regulations. The new cultivation rooms represent approximately 15,000 kg/yr1 of increased target production capacity. These are the first 17 rooms licensed within the Company’s Phase 4B expansion and now brings the Company’s Moncton facility to annualized licensed capacity to a target of 76,000 kg1. The licenses are valid until March 27, 2020 and subject to terms and conditions. “Once again, we are pleased to receive licensing approval consistent with our expectations and the streamlined process we have experienced to date. Our Phase 4 facility expansion remains on schedule to meet growing demand and further contribute to efficiencies of scale,” explains Greg Engel, CEO, Organigram.

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of and The Yield Growth Corp, Winning Media has been paid four thousand five hundred dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer.

Contact Information: